In Brief: Picker International
This article was originally published in The Gray Sheet
Executive SummaryPicker International: Acquires Milwaukee-based Scinticor, manufacturer of the SIM-400 First-Pass cardiac imaging system, for an undisclosed amount. The SIM-400 is the only non-invasive, multi-crystal gamma camera available for medical stress first-pass cardiac imaging procedures. Picker plans to close Scinticor's sole facility in Milwaukee and transfer its manufacturing and distribution services to Picker's Cleveland-based nuclear medicine division. Company officials expect to retain 27 of the 35 Scinticor employees, a plan that includes the integration of the Scinticor sales force into Picker's 200 member domestic sales unit. Scinticor has annual sales of about $6 mil., Picker says...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.